A226950 Stock Overview
OliX Pharmaceuticals, Inc. focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
OliX Pharmaceuticals, Inc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩15,570.00 |
| 52 Week High | ₩25,950.00 |
| 52 Week Low | ₩12,900.00 |
| Beta | 0.82 |
| 1 Month Change | -10.16% |
| 3 Month Change | 7.75% |
| 1 Year Change | -26.21% |
| 3 Year Change | -64.61% |
| 5 Year Change | -53.52% |
| Change since IPO | -52.53% |
Recent News & Updates
Shareholder Returns
| A226950 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 11.7% | 5.4% | 3.4% |
| 1Y | -26.2% | 6.7% | 7.1% |
Return vs Industry: A226950 underperformed the KR Biotechs industry which returned 6.6% over the past year.
Return vs Market: A226950 underperformed the KR Market which returned 4.7% over the past year.
Price Volatility
| A226950 volatility | |
|---|---|
| A226950 Average Weekly Movement | 7.6% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A226950 has not had significant price volatility in the past 3 months.
Volatility Over Time: A226950's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 73 | Dong-Ki Lee | www.olixpharma.com |
OliX Pharmaceuticals, Inc. focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company’s products pipeline includes OLX101A for skin scar; OLX201A for idiopathic pulmonary fibrosis; OLX301 for age-related macular degeneration; and OLX301D for subretinal fibrosis. The company has a collaboration agreement with Théa to develop SiRNA therapeutics for ophthalmic diseases; and a research collaboration with PCI Biotech Holding ASA.
OliX Pharmaceuticals, Inc Fundamentals Summary
| A226950 fundamental statistics | |
|---|---|
| Market cap | ₩257.32b |
| Earnings (TTM) | -₩19.10b |
| Revenue (TTM) | ₩17.06b |
15.1x
P/S Ratio-13.5x
P/E RatioIs A226950 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A226950 income statement (TTM) | |
|---|---|
| Revenue | ₩17.06b |
| Cost of Revenue | ₩159.88m |
| Gross Profit | ₩16.90b |
| Other Expenses | ₩36.01b |
| Earnings | -₩19.10b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.16k |
| Gross Margin | 99.06% |
| Net Profit Margin | -111.94% |
| Debt/Equity Ratio | 70.3% |
How did A226950 perform over the long term?
See historical performance and comparison